RELIEF AFFIRMS INITIATION OF PHASE 2/3 TRIAL OF INHALED RLF-100™ (AVIPTADIL; ZYESAMI™) IN SEVERE COVID-19 PATIENTS
- Top-line data from intravenous RLF-100™ phase 2b/3 trial expected to be released this month
Geneva, Switzerland, February 08, 2021 – RELIEF THERAPEUTICS Holding AG (SIX: RLF, OTCQB: RLFTF) (“Relief” or the “Company”) affirms that its collaboration partner NeuroRx, Inc. has initiated a phase 2/3 clinical trial investigating the role of inhaled RLF-100™ (aviptadil; ZYESAMI™) for the treatment of patients with severe COVID-19 in partnership with UCI Health of the University of California, Irvine. The objective of the current study is to determine whether RLF-100™, administered at the earlier (severe) stage of COVID-19 can reduce the likelihood of progression to critical COVID-19 with respiratory failure: the predominant cause of death in COVID-19-infected individuals. For further information, please refer to: https://relieftherapeutics.com/newsblog/relief-affirms-initiation-of-phase-2-3-trial-of-inhaled-rlf-100-aviptadil-zyesami-in-severe-covid-19-patients
Furthermore, top-line data from the previously completed phase 2b/3 trial of the intravenous (“IV”) formulation of RLF-100™ are slated to be released this month. The statistical analysis of the data remains ongoing. Relief expects top-line data from this trial to be reported once the required statistical analyses have been completed.
Post courtesy of Newsblog
